期刊
BIOMARKERS IN MEDICINE
卷 4, 期 6, 页码 895-903出版社
FUTURE MEDICINE LTD
DOI: 10.2217/BMM.10.104
关键词
biobank; biomarker; cancer; drug development; ethics; guidelines; harmonization; personalized medicine; preanalytical procedures
In recent years, biobanks of human tissues have evolved from small-scale collections of pathological materials into structured resource centers for acquisition, storage, processing and usage of high-quality biospecimens for research. This evolution goes hand in hand with the development of highly sensitive, high-throughput methods for biomarker discovery. The complexity of the molecular patterns of diseases such as cancer provides multiple opportunities for targeted therapeutic intervention, tailored to suit the particular characteristics of each patient. Developing and evaluating such novel therapies requires access to rigorously designed and well-structured collections of biospecimens. In turn, biobanking infrastructures have a critical impact on the discovery, development and implementation of new drugs for cancer treatment. Therefore, it is essential to harmonize biobanking procedures, and to develop innovative solutions supporting biobank interoperability and specimen sharing, ensuring that new drugs may effectively reach out to the largest possible number of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据